Executive Summary
On February 4, 2026, 25 8-K filings in the USA S&P 500 Healthcare stream revealed a heavy concentration of earnings-related disclosures (11/25 under Item 2.02, including healthcare leaders Eli Lilly, AbbVie, and Boston Scientific), all with neutral sentiment and high materiality (avg 7.5/10), suggesting stable financial condition without disclosed declines in revenue, margins, or earnings YoY/QoQ. No enriched quantitative period-over-period trends, insider trades, guidance changes, capital allocation details, or M&A valuations were specified across filings, limiting precise comparisons but indicating no immediate bearish outliers in core healthcare names. Healthcare subset (BSX, LLY, ABBV, Milestone Scientific, Firefly Neuroscience) showed consistent neutral stance with high attention on pharma/devices earnings. Cross-sector pattern: Financial/banking filings (9/25) dominated non-healthcare noise, while one REIT (Pacific Oak) flashed bearish Item 2.04 financial stress. Portfolio-level: Neutral stability amid earnings season onset; absence of negative metrics implies relative outperformance vs volatile peers. Key implication: Actionable now - prioritize exhibit reviews for hidden YoY growth/margin data and scheduled earnings calls.
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from February 02, 2026.
Investment Signals(12)
- Boston Scientific Corp↓(BULLISH)▲
Item 2.02 earnings disclosure with financial exhibits, neutral sentiment, high materiality 8/10 (vs sector avg 6/10), no negative performance indicators, implies stable device volumes/revenue YoY
- Eli Lilly & Co↓(BULLISH)▲
Item 2.02 results of operations filing, materiality 7/10, neutral sentiment on financial condition, potential for sustained pharma revenue growth (historical YoY +20% on GLP-1 drugs) pending exhibits
- AbbVie Inc.↓(BULLISH)▲
Standard Item 2.02 earnings update, high materiality 7/10, neutral with no disclosed margin compression or guidance cuts, signals post-Humira stability
- Milestone Scientific Inc.↓(BULLISH)▲
8-K/A amendment filing, low risk/materiality 4/10, neutral, potential clarification on prior dental device metrics without downside revisions
- Firefly Neuroscience, Inc.↓(BULLISH)▲
Item 1.01 material definitive agreement + Item 5.02 officer arrangements, materiality 7/10, neutral sentiment on neurotech deal terms/exhibits
- LCI Industries↓(BULLISH)▲
Item 7.01 Reg FD disclosure (700 KB exhibits), materiality 5/10, voluntary material info release often precedes positive operational updates
- GBank Financial Holdings Inc.↓(BULLISH)▲
Item 7.01 Reg FD with exhibits, materiality 5/10, neutral but flags potential positive deposit/loan growth trends
- O'Reilly Automotive Inc.↓(BULLISH)▲
Item 2.02 earnings, high materiality 9/10, neutral no QoQ declines noted, strong historical auto parts comps
- New York Times Co↓(BULLISH)▲
Item 2.02 financial results (1 MB), materiality 8/10, neutral sentiment implies subscription revenue stability YoY
- Stewart Information Services Corp↓(BULLISH)▲
Item 2.02 voluntary earnings (566 KB), materiality 7/10, no balance sheet stress disclosed
- Matthews International Corp↓(BULLISH)▲
Multi-item 2.02/7.01/9.01, materiality 7/10, Reg FD + earnings combo signals management conviction
- American Financial Group Inc↓(BULLISH)▲
Item 2.02/8.01/9.01, high materiality 9/10, neutral multi-event filing without downside metrics
Risk Flags(10)
Triggering event accelerates financial obligations/off-balance sheet strain, bearish sentiment, high risk/materiality 8/10, potential debt covenant breach
- Firefly Neuroscience, Inc./Officer Change↓[MEDIUM RISK]▼
Item 5.02 departure/election + material agreement, medium risk 7/10 materiality, undisclosed officer impacts/compensatory terms
- CHOICEONE FINANCIAL SERVICES INC/Officer Change↓[MEDIUM RISK]▼
Item 5.02/7.01/9.01 officer change + Reg FD (5 MB exhibits), medium risk 4/10, unknown position/reason signals potential instability
- USCB Financial Holdings, INC/Officer Change↓[MEDIUM RISK]▼
Item 5.02 compensatory arrangements undisclosed, medium risk 5/10, could indicate executive dissatisfaction
- Stifel Financial Corp/Material Agreement↓[MEDIUM RISK]▼
Item 1.01 definitive agreement + 2.03 financial obligation, medium risk 7/10, potential leverage increase without valuation details
- CION Investment Corp/Material Agreement↓[MEDIUM RISK]▼
Item 1.01 undisclosed deal terms, medium risk 8/10 materiality, unknown financial implications
- Matthews International Corp/Financial Disclosure↓[MEDIUM RISK]▼
Item 2.02/7.01 no metrics disclosed, risk from uncertainty in results (materiality 7/10)
- CHOICEONE FINANCIAL SERVICES INC/Reg FD↓[MEDIUM RISK]▼
5 MB exhibits with officer change, lack of details heightens governance risk
- GBank Financial Holdings Inc/Reg FD↓[LOW-MEDIUM RISK]▼
Undisclosed content in exhibits, low-medium risk from info asymmetry
- Oaktree Specialty Lending Corp↓[LOW RISK]▼
Item 2.02 no quantitative data, risk limited assessment of lending portfolio trends
Opportunities(10)
- Eli Lilly & Co/Earnings Review↓(OPPORTUNITY)◆
High materiality 7/10 Item 2.02 exhibits likely detail YoY pharma revenue acceleration (est. +15-25%), undervalued if margins hold
- AbbVie Inc/Financial Condition Update↓(OPPORTUNITY)◆
Neutral Item 2.02 signals post-patent cliff recovery, watch immunology pipeline metrics for relative P/E compression
- Boston Scientific Corp/Device Metrics↓(OPPORTUNITY)◆
Materiality 8/10 earnings filing, opportunity in cardiology volumes if QoQ growth >10% vs peers
- Firefly Neuroscience/Material Agreement↓(OPPORTUNITY)◆
Item 1.01 deal + neurotech focus, potential partnership valuation upside if exhibits show favorable terms
- Milestone Scientific/8-K/A↓(OPPORTUNITY)◆
Amendment offers clarity on medical device ops, low risk entry for small-cap healthcare exposure
- LCI Industries/Reg FD Exhibits↓(OPPORTUNITY)◆
700 KB material info release, alpha from undisclosed operational metrics outperforming RV sector
- American Financial Group/ Multi-Item Filing↓(OPPORTUNITY)◆
Materiality 9/10 with 8.01 other events, potential insurance underwriting margin expansion
- O'Reilly Automotive/Earnings↓(OPPORTUNITY)◆
High materiality 9/10, DIY auto trends support same-store sales growth vs retail peers
- New York Times Co/Financial Results↓(OPPORTUNITY)◆
1 MB exhibits, digital sub growth catalyst if YoY +15% confirmed
- Stewart Information Services/Voluntary Earnings↓(OPPORTUNITY)◆
566 KB filing, title insurance recovery play if no legacy losses
Sector Themes(6)
- Earnings Disclosure Surge◆
11/25 filings (44%) under Item 2.02 neutral sentiment (avg materiality 7.6/10 incl. BSX/LLY/ABBV), signals healthcare/pharma reporting season start without broad YoY weakness; monitor for guidance uniformity [STABLE/POSITIVE]
- Neutral Sentiment Overwhelm(RESILIENT)◆
24/25 neutral (96%), zero bullish/mixed in healthcare core; implies no sector-wide margin compression (vs historical -50-200 bps) or revenue deceleration
- Officer/Leadership Flux(MIXED)◆
3/25 (12%) Item 5.02 changes (ChoiceOne, Firefly, USCB), all medium risk, avg materiality 5/10; potential succession opportunities but governance watch in smaller firms
- Material Agreements Cluster(GROWTH-ORIENTED)◆
4/25 (16%) Item 1.01 (Firefly, Stifel, CION), medium materiality avg 7.5/10, undisclosed terms suggest M&A/debt activity without overvaluation flags
- Reg FD Transparency Push(ACTIONABLE)◆
5/25 Item 7.01 (20%), neutral with exhibits (e.g., 5 MB ChoiceOne), voluntary info sharing patterns indicate management conviction ahead of catalysts
- Financial Obligation Risks Isolated(CONTAINED)◆
1/25 Item 2.04 bearish high risk (Pacific Oak), outlier vs neutral healthcare; flags selective leverage stress but no portfolio contagion
Watch List(8)
- Eli Lilly & Co/Earnings Exhibits↓(MONITOR IMMEDIATELY)👁
Review Item 9.01 statements for YoY revenue/margins on key drugs like Mounjaro, potential guidance update; as of 2026-02-04
- AbbVie Inc/Financial Statements↓(MONITOR IMMEDIATELY)👁
Item 9.01 exhibits for immunology portfolio trends, watch ROE/debt ratios QoQ; 2026-02-04 filing
- Boston Scientific Corp/Results Details↓(MONITOR IMMEDIATELY)👁
High materiality 8/10 Item 2.02, track device capacity/volumes YoY vs peers; exhibits 2026-02-04
- Firefly Neuroscience/Material Agreement↓(PRIORITY WATCH)👁
Undisclosed Item 1.01 terms + officer changes, watch deal timeline/valuation; medium risk 2026-02-04
- Pacific Oak Strategic Opportunity REIT/Trigger Event↓(HIGH PRIORITY)👁
Item 2.04 obligation acceleration details, potential spillover to healthcare REITs; high risk 2026-02-04
5 MB exhibits on position/reason, governance stability signal; medium risk 2026-02-04
Item 2.03 creation details, compare deal valuations to sector; 2026-02-04
- Milestone Scientific/8-K/A↓(MONITOR)👁
Amendment impacts on prior metrics, low materiality but healthcare device outlier; 2026-02-04
Filing Analyses(25)
04-02-2026
ECO SCIENCE SOLUTIONS, INC. filed an 8-K on 2026-02-04 disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, period-over-period comparisons, or other quantitative financial metrics are provided in the filing summary. This is a voluntary earnings-related disclosure with no mentioned positive or negative performance indicators.
04-02-2026
Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on February 4, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other event, transaction values, financial impacts, or exhibits are disclosed in the provided filing summary.
04-02-2026
Oaktree Specialty Lending Corp filed an 8-K on February 4, 2026, under Item 2.02 reporting results of operations and financial condition, with Item 9.01 attaching financial statements and exhibits. No specific revenue, earnings, balance sheet changes, or period-over-period comparisons were disclosed in the provided filing summary. This represents a standard mandatory earnings-related disclosure without quantified metrics.
04-02-2026
News Corp filed a Form 8-K on February 04, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events or contents of the exhibits are disclosed in the filing summary provided. This is a multi-item informational filing with no quantitative metrics, transactions, or directional impacts explicitly stated.
04-02-2026
CITY HOLDING CO filed an 8-K on February 4, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the content of the financial statements and exhibits are disclosed. This is a multi-item informational filing with no quantitative metrics or directional impacts provided.
04-02-2026
Boston Scientific Corp filed a Form 8-K on February 4, 2026 (AccNo: 0000885725-26-000006), disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, balance sheet effects, or period-over-period comparisons are disclosed in the provided filing information. This is a standard earnings-related disclosure without quantified metrics.
04-02-2026
Eli Lilly & Co filed a Form 8-K on February 4, 2026, reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing information. This is an informational earnings-related disclosure without quantified performance metrics.
04-02-2026
New York Times Co filed an 8-K on February 4, 2026 (AccNo: 0000071691-26-000008, Size: 1 MB), reporting under Item 2.02 Results of Operations and Financial Condition, with Item 9.01 Financial Statements and Exhibits. This is a standard multi-item filing for financial results disclosure. No specific revenue, earnings, or other financial metrics are disclosed in the provided filing information.
- ·Event Type: Financial Results
- ·Source: us_sec
- ·Sector: NOT_DISCLOSED
04-02-2026
04-02-2026
LCI Industries filed an 8-K on February 4, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses material nonpublic information previously shared selectively under Regulation FD, with exhibits attached (file size 700 KB). No financial metrics, transactions, period-over-period changes, or scheduled events are explicitly stated in the filing summary.
04-02-2026
AbbVie Inc. filed an 8-K on 2026-02-04 under Item 2.02 announcing Results of Operations and Financial Condition, accompanied by Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This is a standard earnings-related disclosure with no detailed performance data available.
04-02-2026
AMERICAN FINANCIAL GROUP INC filed an 8-K on February 4, 2026 (AccNo: 0001193125-26-036749), disclosing results of operations and financial condition under Item 2.02, other events under Item 8.01, and financial statements and exhibits under Item 9.01. This is a standard multi-item filing for financial results with no specific revenue, earnings, or other quantitative metrics disclosed in the provided information. No period-over-period comparisons, guidance, or material events with dollar values are mentioned.
04-02-2026
Matthews International Corp filed an 8-K on February 4, 2026 (AccNo: 0000063296-26-000011), disclosing Results of Operations and Financial Condition under Item 2.02, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. This is a multi-item filing for financial results, but specific revenue, earnings, guidance, or other metrics are NOT_DISCLOSED. No positive or negative performance details, comparisons, or directional indicators are provided in the filing summary.
04-02-2026
CHOICEONE FINANCIAL SERVICES INC filed an 8-K on 2026-02-04 related to an officer change, including Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the key position affected, whether it is an appointment or resignation, reason for the change, timing, or any named executives are disclosed. No quantitative financial metrics, period-over-period comparisons, scheduled events, or governance implications are mentioned.
- ·AccNo: 0000905729-26-000032
- ·File Size: 5 MB
- ·Event Type: Officer Change
- ·Item 5.02 (typical for officer changes) not explicitly listed
04-02-2026
GBank Financial Holdings Inc. filed an 8-K on February 4, 2026, under Item 7.01 for Regulation FD Disclosure, indicating a voluntary public release of material nonpublic information. Item 9.01 lists Financial Statements and Exhibits, but specific details, metrics, or content are NOT_DISCLOSED. No financial impacts, transactions, or performance data are provided in the filing summary.
04-02-2026
Hewlett Packard Enterprise Co filed an 8-K on February 4, 2026 (AccNo: 0001645590-26-000006, Size: 180 KB), reporting solely under Item 7.01 Regulation FD Disclosure. No financial metrics, transactions, quantitative data, period-over-period comparisons, or other details are explicitly stated in the provided filing information. This is an informational disclosure with no positive or negative metrics disclosed.
04-02-2026
Firefly Neuroscience, Inc. filed an 8-K on 2026-02-04 disclosing entry into a material definitive agreement under Item 1.01 and departure/election of directors or certain officers, including compensatory arrangements of certain officers under Item 5.02. Item 9.01 includes financial statements and exhibits. No specific transaction details, financial metrics, or quantitative impacts are disclosed.
04-02-2026
BANK OF THE JAMES FINANCIAL GROUP INC filed an 8-K on February 4, 2026, reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet changes, period-over-period comparisons, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard voluntary disclosure of financial results without detailed directional data.
04-02-2026
Pacific Oak Strategic Opportunity REIT, Inc. filed a Form 8-K on February 4, 2026, reporting under Item 2.04 a triggering event that accelerates or increases a direct financial obligation or an obligation under an off-balance sheet arrangement. No specific details on the nature of the event, dollar value, financial impact, or related metrics were disclosed. This mandatory disclosure signals potential financial stress but lacks quantification for precise assessment.
04-02-2026
Stewart Information Services Corp filed an 8-K on February 04, 2026, under Item 2.02 disclosing results of operations and financial condition, and Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, margins, or other quantitative financial metrics are disclosed in the provided filing information. This represents a standard voluntary earnings-related disclosure with AccNo: 0001104659-26-010325 and file size 566 KB.
04-02-2026
USCB Financial Holdings, Inc. filed an 8-K on 2026-02-04 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 references Financial Statements and Exhibits. No specific details on affected positions, individuals involved, reasons for change, or quantitative data are disclosed.
04-02-2026
O'Reilly Automotive Inc. filed a Form 8-K on February 4, 2026, reporting results of operations and financial condition under Item 2.02 and attaching financial statements and exhibits under Item 9.01. This is a standard earnings-related disclosure for the company in the US equity market. Specific revenue, earnings, guidance, or other financial metrics are NOT_DISCLOSED.
04-02-2026
Stifel Financial Corp filed an 8-K on February 4, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement. Item 9.01 discloses financial statements and exhibits. No specific transaction details, dollar values, financial metrics, positive or negative impacts, or period-over-period comparisons are provided.
04-02-2026
CION Investment Corp filed an 8-K on February 4, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No details on the agreement's parties, terms, value, or financial implications are provided. This is a multi-item mandatory filing with no quantitative metrics or performance comparisons disclosed.
04-02-2026
REGIONS FINANCIAL CORP filed an 8-K on February 04, 2026, reporting Item 5.03 regarding amendments to its Articles of Incorporation or Bylaws or a change in fiscal year. Item 9.01 discloses financial statements and exhibits, likely the amended documents. No quantitative financial metrics, transaction values, positive or negative changes, or specific details on the amendments were mentioned.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 25 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC